Prognostic value of circulating dead monocytes in patients with acute st-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
This study tested the hypothesis that the level of apoptotic and necrotic peripheral blood mononuclear cells (PBMCs) is a predictor of the 30-day combined major adverse clinical outcome (MACO) [defined as advanced congestive heart failure (CHF), a high Killip score, or 30-day mortality] in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). Between April 2009 and January 2010, 98 patients undergoing primary PCI were assessed for both apoptotic and necrotic PBMCs (apoptotic cells are referred to as annexin V+/propidium iodide- and necrotic cells are defined as annexin V+/propidium iodide+) using flow cytometry 24 h after STEMI. Patients with higher (≥ 3.2%) and lower (<3.2%) levels of necrotic cells were categorized into group 1 (n = 40) and group 2 (n = 58), respectively, according to the ROC curve method. Higher incidences of advanced CHF and a high Killip score were noted in group 1 patients (p < 0.0001). Moreover, the peak level of creatine phosphokinase was higher in group 1 (p < 0.0001), whereas the left ventricular ejection fraction was lower in group 1 than in group 2 (p < 0.001). Multivariate analysis revealed that high necrotic cells (≥ 3.2%) was the strongest independent predictor of 30-day MACO (p = 0.001). A high level of necrotic cells (PBMCs) may serve as a useful biomarker for predicting 30-day MACO in patients with STEMI undergoing primary PCI.